As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh carries a market capitalization of 53.86B, placing it among publicly traded companies globally. Its enterprise value stands at 47.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 53.86B |
| Enterprise Value | 47.31B |
As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh has 19.24M shares outstanding.
| Shares Outstanding | 19.24M |
As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh trades at a trailing price-to-earnings ratio of 26.36. The price-to-sales ratio is 0.97, and the price-to-book ratio stands at 1.69.
| PE Ratio | 26.36 |
| PS Ratio | 0.97 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 2.02 |
As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh trades at an EV/EBITDA multiple of 15.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 47.31B versus a market cap of 53.86B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.83 |
| EV / EBITDA | 15.30 |
As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh maintains a current ratio of 2.45, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.45 |
| Quick Ratio | 1.30 |
| Debt / Equity | 30.81 |
| Debt / EBITDA | 3.18 |
Over the twelve months ended June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh posted a return on equity (ROE) of 7.25, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.08, measuring how efficiently the asset base is converted into earnings. The company generates approximately 641.89M in revenue per employee across its workforce of 89.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.63 indicates how many times Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 7.25 |
| Return on Assets (ROA) | 4.08 |
| Revenue Per Employee | 641.89M |
| Employee Count | 89.25 |
| Inventory Turnover | 6.63 |
Over the twelve months ended June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh recorded 7.64M in income tax expense. The company reported a pretax loss of -1.80B and 2.10B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 7.64M |
As of the close on November 17, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh's stock has declined approximately 28.88% over the past 52 weeks. The 50-day moving average sits at 2,962.50, while the 200-day moving average is 3,190.45.
| 52-Week Price Change | -28.88% |
| 50-Day Moving Average | 2,962.50 |
| 200-Day Moving Average | 3,190.45 |
Over the twelve months ended June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh generated 57.29B in revenue and converted that into 2.10B in net income, yielding earnings per share of -91.27. EBITDA reached 3.09B, while operating income came in at -817.61M.
| Revenue | 57.29B |
| Gross Profit | 14.46B |
| Operating Income | -817.61M |
| Pretax Income | -1.80B |
| Net Income | 2.10B |
| EBITDA | 3.09B |
| EBIT | -817.61M |
| Earnings Per Share (EPS) | -91.27 |
As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh holds 16.40B in cash and equivalents against 9.85B in total debt, resulting in a net debt position of -9.35B. Total book value stands at 31.95B, with working capital of 18.25B providing operational flexibility.
| Cash & Cash Equivalents | 16.40B |
| Total Debt | 9.85B |
| Net Debt | -9.35B |
| Equity (Book Value) | 31.95B |
| Book Value Per Share | 1,661.12 |
| Working Capital | 18.25B |
These figures cover the twelve months ended June 30, 2026.
| Capital Expenditures | -622.62M |
Over the twelve months ended June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh posted a gross margin of 25.23, reflecting its pricing power and cost economics. The operating margin of -1.43 and net profit margin of 3.66 provide insight into operational efficiency.
| Gross Margin | 25.23 |
| Operating Margin | -1.43 |
| Pretax Margin | -3.13 |
| Profit Margin | 3.66 |
| EBITDA Margin | 5.40 |
As of June 30, 2026, Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh has an Altman Z-Score of 3.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.78 |